Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) reported a 35.9% year-over-year drop in consolidated net profit in the fiscal first quarter, weighed down by ballooning expenses that offset the 22% jump in revenue.
Net profit plunged to 9.40 billion rupees from 14.7 billion rupees a year earlier, with earnings per share also falling to 9.35 rupees from 14.58 rupees, the Indian drugmaker said in a bourse filing on Tuesday.
Meanwhile, revenue from operations rose 22% to 80.2 billion rupees, the company's highest quarterly revenue on record, from 65.7 billion rupees a year ago.
In a presentation on Tuesday, Zydus attributed the revenue growth to its core pharmaceutical business as India-branded formulations sustained robust growth momentum and outpaced the market growth for another quarter.
The company said its North America formulations business expanded sequentially on the back of sustained volume expansion and new product launches.
However, larger expenses hit the company's bottom line as total expenses ballooned to 25.4 billion rupees from 22.7 billion rupees.
During the quarter, Zydus booked severance compensation of 1.09 billion rupees tied to its acquisition of Assertio Holdings. It also booked 559 million rupees as a provision to settle a class action lawsuit.
Looking ahead, Zydus reaffirmed its fiscal 2027 outlook for strong double-digit revenue growth and an EBITDA margin of 24% or more.
During an earnings call, Zydus CFO Tushar Shroff said the company expects 30 to 40 new US product launches in the current fiscal year.



